Literature DB >> 23373849

Preliminary evaluation of a new clinical algorithm to interpret blood cultures growing coagulase-negative staphylococci.

David Schnell1, Hervé Lécuyer, Thomas Geeraerts, Anne-Sylvie Dumenil, Emmanuelle Bille, Frédéric J Mercier, Dan Benhamou, Jean-Ralph Zahar.   

Abstract

Evaluating the clinical significance of blood cultures positive for coagulase-negative staphylococci (CoNS) is of critical importance since these microorganisms represent both the first contaminants of blood cultures and one of the leading causes of bloodstream infection (BSI). This prospective 2-centre study aimed to compare a previously reported algorithm to a clinical algorithm based on our experience. We identified 84 patients with CoNS-positive blood cultures. Twenty-seven (32%) were considered to have BSI according to our study algorithm. Thirty-seven (44%) patients were considered to have CoNS BSI according to the previously reported algorithm. The 2 algorithms isolated patients with similar rates of recurrences and hospital mortality. Our algorithm seemed to result in less diagnoses of CoNS BSI without harmful consequences compared to the previously reported algorithm. The impact on patient outcome and the inappropriate use of antibiotics deserves further investigation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23373849     DOI: 10.3109/00365548.2013.765590

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  2 in total

1.  [Distribution and drug resistance of pathogens of blood stream infection in patients with hematological malignancies after chemotherapy].

Authors:  S Z Chen; K N Lin; M Xiao; X F Luo; Q Li; J H Ren; R Y Huang; M M Chen; Z Z Ally; T Chen; J D Yang; Jianda Hu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-11-14

2.  Antibiotic resistance of blood cultures in regional and tertiary hospital settings of Tyrol, Austria (2006-2015): Impacts & trends.

Authors:  Peter Kreidl; Thomas Kirchner; Manfred Fille; Ingrid Heller; Cornelia Lass-Flörl; Dorothea Orth-Höller
Journal:  PLoS One       Date:  2019-10-10       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.